Ingenuity Announces Licensing Agreement with Boehringer Ingelheim
News Apr 19, 2006
Ingenuity Systems has announced that they have entered into an agreement with Boehringer Ingelheim for global access to Ingenuity Pathways Analysis (IPA) software.
"Boehringer Ingelheim's research teams will now have broad access to IPA globally at all sites," stated Peter DiLaura, Vice President, Sales and Customer Support.
"By integrating IPA into their workflows, researchers will shorten the time between data generation and biological interpretation. This value comes from the ability to understand biology at multiple levels - molecular interactions, association with cellular phenotypes, and understanding disease processes."
Ingenuity Pathways Analysis is a software application that is designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.
IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally.
It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.
Ingenuity Pathways Analysis is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available online.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.